A generic equivalent to Zemplar (paricalcitol; AbbVie) Capsules has been made available by Teva Pharmaceuticals

Zemplar Capsules are an active form of vitamin D used to prevent and treat secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease and in Stage 5 patients on dialysis.  

RELATED: Urological Disorders Resource Center

The biological effects of paricalcitol are mediated through binding of the vitamin D receptor, which results in the selective activation of the vitamin D responsive pathways. 

Vitamin D and paricalcitol have been shown to reduce parathyroid hormone levels by inhibiting parathyroid hormone synthesis and secretion.

Paricalcitol Capsules from Teva are available in 1mcg, 2mcg, and 4mcg strengths in 30-count bottles.

For more information call  (888) 838-2872 or visit TevaGenerics.com.